Boston, MA: CRYTUR spol s.r.o. announces the opening of a US branch in Boston, MA to provide enhanced support to a rapidly expanding field of North American customers. The US company, Crytur USA, will offer the same high quality products, services and technical support as their customers came to expect from CRYTUR.
The company offers a diverse portfolio of products and integrated solutions based on several decades of experience in growing crystals with applications in high-performance lasers, radiation detectors, medical imaging, sapphire profiles, high-intensity light sources. In addition, Crytur designs and manufactures precision optical elements, ceramics and ferrites. Their customer base varies from small university groups to multinational corporations, to national laboratories.
The US team adds considerable expertise in the areas of the scintillator materials, design of specialized radiation detector systems, design of radiation detectors for harsh environments, medical applications, security applications and electronics design for highly customized applications.
Gurugram, July 08, 2020: Signature Global, India’s no. 1 Affordable Housing Company, announced the launch of its 20th Housing Project ‘Golf Greens 79’ in Sector 79, Gurugram. The project is launched under the Haryana Affordable Housing Policy and its cost is Rs 225 crore. Away from the hustle-bustle and set in the foothills of Aravallis, it will have 1 and 3 BHK options with a total number of 852 housing units. Located near commercial hubs of Sector 74A and Sector 75A, the prices at Signature Global ‘Golf Greens 79’ starts from Rs 14.46 lakh for 1 BHK and Rs 25.80 lakh for 3 BHK.
Signature Global ‘Golf Greens 79’ is a few minutes away from NH8 and very well connected to Southern Peripheral Road, and KMP Expressway. Some of the landmarks in the proximity of the project include Aapno Ghar- water and amusement park, ITC Grand Bharat, Hyatt Regency, Golden Green Golf & Resorts, Heritage Village Resorts. Many other landmark residential projects are in the vicinity whereas a lot of educational institutions and hospitals are close by.
Commenting on the impeccable record of delivery, Mr. Pradeep Aggarwal, Founder & Chairman, Signature Global Group and Chairman, ASSOCHAM, National Council on Real Estate, Housing and Urban Development said, “The demand for affordable housing has increased manifold. In the post-COVID-19 situation, people are expected to get hold of a good property to call their home. The realization of the importance of one’s home has dawned on people while staying and working from home as many of them have faced challenges. ”
For faster delivery of projects, the company deploys innovative technologies to ensure speed, efficiency, and quality of construction. AFW (aluminum formwork) ensures fast and quality construction while the projects promises to look perfect as the Padma Shri Architect Hafeez Contractor is designing it. “We are dedicated to deliver affordable houses on time and our focus on timely delivery comes with maintaining the quality standards at the same time. To contribute to the mission of ‘Housing for All’ by 2022, we announce that today everyone irrespective of limited budget can afford a comfortable house and should invest into real estate considering that it is the safest asset,” Mr. Aggarwal added.
Chennai, 08 July 2020: The Bailadila Projects of NMDC at Chattisgarh, the country’s largest Navratna mining company, recorded a sharp rise in sales and production in June 2020 as compared to June 2019, despite the lockdown that had been imposed due to the current COVID-19 scenario and was also closed due to various factors for seven days last month.
Last month, the Bailadila Projects registered a production of 18.61 lakh tonnes as compared to the total production of 17.72 lakh tonnes in the corresponding month of June last year, an increase of 5 percent in the total production.
The Kirandul unit of the Bailadila Projects has also achieved a new record in sales during the above period. Last year, while 8.47 lakh tonnes of iron ore were sold from Kirandul unit in the month of June, in the month of June 2020, the total sales were 10.47 lakh tonnes, which is 24% higher than the previous year.
Shri N. Baijendra Kumar, IAS, CMD, NMDC
Shri N. Baijendra Kumar, IAS, Chairman cum Managing Director of NMDC, commented that, “This is a wonderful achievement in increasing production and sales by the personnel of the Bailadila Projects under adverse and stressful circumstances. The colleagues at Bailadila played an important role in keeping the wheels of the industry running in line with the motto Har ek kaam, Desh ka naam”.
Mr. Kumar also said that NMDC has ensured that all necessary measures are implemented to meet the challenges posed by the Covid-19 virus and that production is sustained. He said that NMDC values employees the most and every step will be taken to protect our personnel from this epidemic.
NMDC along with all its personnel is moving in step with the country in the fight against Covid-19. He said that NMDC has made special arrangements for social distancing, hand-sanitation and sanitization at all its offices and project sites. Regular health check-up of personnel at all offices and project sites are undertaken at regular intervals so that production is not hampered and can be increased while ensuring effective protection from Covid-19.
MIAMI, Florida/Mumbai – July 7, 2020 –Cruise industry leaders Royal Caribbean Group and Norwegian Cruise Line Holdings Ltd. announced a collaboration to develop enhanced cruise health and safety standards in response to the global COVID-19 pandemic.
The companies have asked Governor Mike Leavitt and Dr. Scott Gottlieb to serve as co-chairs of a newly formed group of experts called the “Healthy Sail Panel.” The panel is tasked with collaboratively developing recommendations for cruise lines to advance their public health response to COVID-19, improve safety, and achieve readiness for the safe resumption of operations.
The expert panel has been working for nearly a month and will offer its initial recommendations by the end of August. The cruise lines said its work will be “open source,” and could be freely adopted by any company or industry that would benefit from the group’s scientific and medical insights.
“This unprecedented disease requires us to develop unprecedented standards in health and safety,” said Richard D. Fain, chairman and CEO of Royal Caribbean Group. “Bringing aboard these respected experts to guide us forward demonstrates our commitment to protecting our guests, our crews and the communities we visit.”
“We compete for the vacationing consumer’s business every day, but we never compete on health and safety standards,” said Frank Del Rio, president and CEO of Norwegian Cruise Line Holdings Ltd. “While the cruise industry has always had rigorous health standards, the unique challenges posed by COVID-19 provide an opportunity to raise the bar even higher.”
“Health and safety” are the priority for all CLIA cruise line members as demonstrated by this initiative on the part of two of our largest members. We commend this and parallel efforts of all of our members, large and small, who are working tirelessly to develop appropriate protocols based on input from health authorities and medical experts in the U.S. and abroad,” said Kelly Craighead, president and CEO of Cruise Lines International Association (CLIA).
Fain and Del Rio said they initiated the panel to assure the plans they will submit to the U.S. Centers for Disease Control and Prevention (CDC) and other regulators apply the best available public health, science and engineering insights. The work of the panel will be shared with the entire industry and regulators.
“In convening the Healthy Sail Panel, we sought the participation of a diverse group of leading experts in areas of science and public health that are directly relevant to the considerations listed by the No Sail Order,” said Governor Leavitt. “We view our work as a profoundly important public health effort. The health and safety of passengers, crew, and the communities that cruise ships visit will be the principal focus of this project.”
Dr. Gottlieb said, “We know that the public health issues that must be addressed are complex, and in some areas, tackling them will require novel approaches. Our goal in assembling this team of leading experts was to develop best practices that can improve safety and provide a roadmap for reducing the risks of COVID-19.”
The panel is co-chaired by Governor Leavitt, former Secretary of the U.S. Department Health and Human Services (HHS), and Dr. Scott Gottlieb, former commissioner of the U.S. Food and Drug Administration (FDA). The panel’s members are globally recognized experts from various disciplines, including public health, infectious disease, biosecurity, hospitality and maritime operations.
The members of the expert panel are: Governor Mike Leavitt
Mike Leavitt was a three term Governor of Utah and served as Administrator of the EPA and Secretary of HHS under President George W. Bush. He is the founder of Leavitt Partners, a firm that provides investment support, data and analytics, member-based alliances, and direct services to clients to support decision-making strategies in the value economy. Dr. Scott Gottlieb
Dr. Scott Gottlieb was the Commissioner of the FDA from 2017-2019 and served as the agency’s Deputy Commissioner for Medical and Scientific Affairs from 2005-2007. He is a physician trained in internal medicine and is currently a resident fellow at the American Enterprise Institute.
Helene Gayle MD, MPH
Dr. Gayle is CEO of the Chicago Community Trust, one of the nation’s leading community foundations. Prior to this role, foralmost a decade, she was president and CEO of CARE, a leading international humanitarian organization. An expert on global development, humanitarian and health issues, Dr. Gayle spent 20 years with the CDC, working primarily on HIV/AIDS. She worked at the Bill & Melinda Gates Foundation, directing programs on HIV/AIDS and other global health issues. She also launched the McKinsey Social Initiative (now McKinsey.org), a nonprofit that builds partnerships for social impact. Dr. Gayle serves on public company and nonprofit boards, including The Coca-Cola Company, Colgate-Palmolive Company, the Brookings Institution, the Center for Strategic and International Studies, New America, the ONE Campaign, the Federal Reserve Bank of Chicago and the Economic Club of Chicago. She is a member of the Council on Foreign Relations, the American Public Health Association, the National Academy of Medicine, the National Medical Association and the American Academy of Pediatrics.
Julie Gerberding, MD, MPH
Dr. Julie L. Gerberding is Executive Vice President and Chief Patient Officer for Merck, leading all aspects of strategic communications, global public policy, population health and patient engagement.
A former head of the CDC and a world-renowned public health expert, Dr. Gerberding is deeply committed to achieving sustainable global health impact and tackling some of the most challenging health priorities of our time. This includes addressing critical issues such as affordable access to important therapies, advocating for health policies that promote and sustain innovation of new medicines and vaccines, and improving maternal mortality through the Merck for Mothers program — a public-private partnership helping to meet the United Nations’ Sustainable Development Goal to reduce maternal mortality.
Prior to joining Merck, Dr. Gerberding served as the Director of the CDC from 2002-2009 and was the first female to hold that position. While at the agency, she led more than 40 emergency responses against crises such as anthrax, SARS, bird flu, food-borne outbreaks and natural disasters. Previously, Dr. Gerberding was a tenured faculty member in Infectious Diseases at the University of California at San Francisco (UCSF). She continues as an Adjunct Associate Clinical Professor of Medicine at UCSF.
Steven Hinrichs, MD
Dr. Steven Hinrichs is Professor and Chair in the Department of Pathology and Microbiology at the University of Nebraska Medical Center in Omaha and the Director of the Nebraska Public Health Laboratory (NPHL), and Director of the University of Nebraska Center for Biosecurity. In his position as laboratory director he has been responsible for the development of a statewide program for the rapid identification of biological agents of mass destruction. He is principal investigator of multiple national awards from the Association of Public Health Laboratories (APHL) and the CDC and the U.S. Department of Defense for the development of an outreach program to extend training and expertise in the early recognition of biological warfare agents. Dr. Hinrichs received his MD from the University of North Dakota and is board certified in Anatomical and Clinical Pathology. His research laboratory focuses on molecular diagnostics and the role of viruses in cancer. Dr. Hinrichs has published over 130 papers in basic science and medical journals.
Michael Osterholm, MD, PhD
Michael Osterholm is one of the nation’s foremost experts in public health, infectious disease and biosecurity. As the director of the Center for Infectious Disease Research and Policy at the University of Minnesota, he is an international leader on the world’s preparedness for pandemics. He has led numerous investigations into internationally important disease outbreaks, including foodborne diseases, hepatitis B in health care settings, and HIV infection in healthcare workers, and he is a frequent consultant to the World Health Organization, the National Institutes of Health, the FDA, the U.S. Department of Defense and the CDC. From 2001 to 2005, Dr. Osterholm served as a special advisor to the Secretary of HHS on issues related to bioterrorism and public health preparedness. From June 2018 through May 2019, he served as a Science Envoy for Health Security on behalf of the U.S. Department of State. He has also been appointed to the National Science Advisory Board on Biosecurity and the World Economic Forum’s Working Group on Pandemics, among other prominent advisory positions
Stephen Ostroff, MD
Dr. Ostroff brings years of experience in public health, having served at high level positions at the FDA and CDC. He was the Acting Commissioner of the FDA from 2015-2016, and before that served as the FDA’s chief scientist. Ostroff joined the FDA in 2013 as chief medical officer in the Center for Food Safety and Applied Nutrition and senior public health advisor to FDA’s Office of Foods and Veterinary Medicine. Prior to that he served as deputy director of the National Center for Infectious Diseases at the CDC, where he was also acting director of CDC’s Select Agent Program. While at the CDC he focused on emerging infectious diseases, food safety, and coordination of complex outbreak response. He retired from the Commissioned Corps of the U.S. Public Health Service at the rank of Rear Admiral (Assistant Surgeon General). Ostroff was also the director of the Bureau of Epidemiology and acting physician general for the Commonwealth of Pennsylvania and has consulted internationally on public health projects in South Asia and Latin America. Ostroff graduated from the University of Pennsylvania School of Medicine in 1981 and completed residencies in internal medicine at the University of Colorado Health Sciences Center and preventive medicine at CDC.
William Rutala, PhD, MS, MPH
Dr. Rutala has experience medically managing a variety of diseases and extensive experience studying epidemiology and virology, particularly managing outbreaks and emerging pathogens. Dr. Rutala’s research interests are the etiology and prevention of healthcare-associated infections with a special focus on disinfection and sterilization of reusable medical and surgical devices (e.g., endoscopes, surgical instruments). Other areas of active research include contribution of the hospital environment to disease transmission, hand hygiene, preventing transmission of infectious agents, including multiple-drug resistant organisms, prevention of healthcare-associated Creutzfeldt-Jakob Disease, investigation of healthcare-associated outbreaks, and new and emerging pathogens in healthcare.
Kate Walsh, PhD
Kate Walsh is the Dean at the School of Hotel Administration at Cornell University and E.M. Statler Professor. A professor of management, she is a leader in education for the global hospitality industry; and a renowned expert in organizational service design, leadership and career development, as well as the impact of strategic human capital investments. In addition to authoring and contributing to books, Dr. Walsh’s articles have appeared in numerous research outlets. She has over 20 years of academic experience, including in her current role as dean.
In addition, Dean Walsh holds extensive industry knowledge from serving as the former director of training and development for Nikko Hotels International, corporate training manager for the former Bristol Hotels, and senior auditor for Loews Corporation. She is also a former New York State Certified Public Accountant. Since the beginning of her administration as dean, Dean Walsh has focused on positioning the school for the future of education. This includes undertaking a comprehensive renewal of the graduate and undergraduate curricula, developing the school’s online global presence, identifying international partners for master-level program development, and providing thought leadership for the hospitality industry, most notably through the creation of industry research partnerships for faculty, fostering new initiatives through the school’s six centers and institutes, and providing faculty-developed resources to guide the industry. Dr. Walsh received her Ph.D. from the Carroll School of Management at Boston College and her M.P.S. degree from Cornell’s School of Hotel Administration.
Captain Patrik Dahlgren
Captain Patrik Dahlgren is the Senior Vice President of Global Marine Operations and Fleet Optimization for all Royal Caribbean Group global brands. Dahlgren’s seagoing experiences started as a bridge officer aboard tugboats, yachts and an array of cargo vessels and ferries. He rose through the ranks with over 15 years onboard Royal Caribbean International cruise ships, with his last seagoing command as Master of Oasis of the Seas and Quantum of the Seas. He was a lead contributor to the Quantum of the Seas development and received the esteemed RINA (Royal Institute of Naval Architects) award for its innovation and contributions to maritime safety.
Robin Lindsay
Robin Lindsay is the Executive Vice President of Vessel Operations for Norwegian Cruise Line Holdings Ltd. Lindsay was appointed to this position in January 2015. In this role, Lindsay is responsible for Marine & Technical Operations, Hotel Operations, Entertainment, Product Development, Port & Destination Services, Fleet Personnel, Out Islands and New Build & Ship Refurbishment for all three of the company’s brands – Norwegian Cruise Line, Oceania Cruises and Regent Seven Seas Cruises.
Prior to joining Norwegian Cruise Line Holdings Ltd., Lindsay served in a similar capacity as Executive Vice President of Vessel Operations at Prestige Cruise Holdings, the parent company of Oceania Cruises and Regent Seven Seas Cruises. Lindsay’s history with the company goes back to the inception of Oceania Cruises in 2003, where he joined as Senior Vice President, Hotel Operations and Vessel Operations. Lindsay earned his B.S. degree from Louisiana Tech University.
In addition, several experts will also serve as senior advisors to the panel, including Dr. Caitlin Rivers, who is a faculty member and epidemiologist at the Johns Hopkins Bloomberg School of Public Health and an expert in emerging infectious disease epidemiology and outbreak science, and Dr. Phyllis Kozarsky, who is a professor emerita of medicine in the Division of Infectious Diseases at Emory University School of Medicine and an expert in pre-travel health advice and education, global health, and the epidemiology of travel related infections and infectious diseases. Dr. Kozarsky serves as an expert consultant to the Division of Global Migration and Quarantine in travelers’ health with the CDC.
Chennai, July 8, 2020: Rossari Biotech Limited, a leading specialty chemicals manufacturer (Source: F&S Report) focusing on home, personal care and performance chemicals will be launching its initial public offering on Monday, July 13, 2020 and will close on Wednesday, July 15, 2020, with a price band of ₹ 423 – ₹ 425 per Equity Share. Bids by anchor investors shall be submitted, and allocation to them will be completed on July 10, 2020, being one working day prior to the Offer opening date.
As mentioned in the red herring prospectus dated July 4, 2020 (“RHP“), filed by Company with the Registrar of Companies, Maharashtra at Mumbai (“RoC”), the Company raised ₹ 999.99 million in a private placement of 2,352,920 Equity Shares to various investors including Malabar India Fund Limited, Axis New Opportunities AIF-I , Mirae Asset Mid Cap Fund, Sundaram Mutual Fund A/C Sundaram Select Micro Cap Series – XIV, IIFL Special Opportunities Fund – Series 4 and ICICI Lombard General Insurance Company Limited (“Pre-IPO Placement”). The size of the fresh issue of up to ₹ 1,500 million has been reduced by ₹ 999.99 million pursuant to the Pre-IPO Placement, and accordingly, the size of the fresh issue is up to ₹ 500 million.
The Offer is being made in accordance with Regulation 19(2)b of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (“SEBI ICDR Regulations”) through book building process wherein not less than 15% of the Offer shall be available for allocation on a proportionate basis to non-institutional investors and not less than 35% of the Offer shall be available for allocation to retail individual investors in accordance with the SEBI ICDR Regulations.
The proceeds of the Fresh Issue (less the Offer expenses) and the proceeds from the Pre-IPO Placement are proposed to be utilized to repay/prepay borrowings availed by the Company of ₹ 650 million, to fund its working capital requirements of ₹ 500 million and towards general corporate purposes. The Company will not receive any proceeds from the Offer for Sale.
Axis Capital Limited and ICICI Securities Limited have been appointed as the book running lead managers to the Offer and Axcelus Finserv Private Limited was appointed as advisor to the Offer. The Equity Shares offered through the RHP shall be listed on National Stock Exchange of India Limited (“NSE”) and BSE Limited (“BSE”). Link Intime India Private Limited is the registrar to the Offer.
Additionally, in fiscal year 2020, the Company generated total revenues of ₹ 6,038.18 million and a net profit after tax of ₹ 652.53 million. Over the last 3 years, it has managed to clock a compounded annual growth rate of 41.65% for its revenues and a compounded annual growth rate of 60.27% for its profit after tax. The debt equity ratio of the company stood steady at 0.23 across fiscal years 2018-2020
According to the report titled “Global and Indian Specialty Chemicals Report” dated December 10, 2019, prepared by Frost & Sullivan (India) Private Limited (“F&S”, and such report, the “F&S Report“), the Company was the largest manufacturer of textile specialty chemicals in India as on September 30, 2019, and is a leading manufacturer of acrylic polymers in India. As stated in the RHP, the Company plans to venture into the construction chemicals market and water treatment formulations market. The global specialty chemicals market cumulatively constitutes a global market of approximately USD 237 billion in 2018 and is expected to grow at 5.4% per annum to reach approximately USD 308 billion by 2023. The Company’s presence in the specialty chemicals market, particularly in the home, personal care and performance chemicals; textile specialty chemicals; and animal health and nutrition products, presents significant growth opportunities due to the following factors: (i) demographic overview and rapid urbanisation leading to consumption growth, (ii) growing demand for environmentally sustainable chemicals and (iii) positive regulatory focus from the Indian governmental authorities on manufacturing activities in India. (Source: F&S Report).
Dubai, United Arab Emirates, July 01, 2020: Prism Digital, a full-service digital marketing company, has won the digital mandate for Museum of Illusions, Dubai which is one of the most popular tourist attractions in Al Seef by Meraas. This business was won after a Pan Arab Multi-agency pitch conducted earlier this year.
As a part of the mandate, Prism will handle digital advertising, social media marketing, Google AdWords, SEO, and online reputation management. Prism with its core expertise in digital marketing and advanced creative approach will be managing their social media footprints with authentic content and capture live actions at the museum during operation.
Commenting on the association with Prism, Varvara Bonnet, Museum Manager Museum of Illusions, expressed, “We have selected Prism after a comprehensive pitch process. They understood our business and have tremendous experience handling major Dubai Tourism Projects. 90% of our business comes from Tourists and we are confident that Prism’s strategic approach towards our digital marketing management will go a long way in making Museum of Illusions, a well-known tourist attraction amongst visitors visiting Dubai.”
Prism is one of the leading Digital marketing agencies in Dubai and caters to 150 clients from different sectors from Large Corporate and brand to real estate and Food and beverage brands. they also manage some of the largest brands in the Medical services segments. Established in the year 2006 they are also a preferred Google Partner Agency as a Facebook Preferred Partner.
Speaking about the win, Mr. Lovetto Nazareth, Director Prism Digital comments “We couldn’t be more thrilled to partner with Museum of Illusions, Dubai. Our ROI focussed lead generation methodology and digital marketing strategies have grown the business by 3x even in a situation where there was a 90% drop in footfalls and traffic into the Al Seef Area for a couple of months due to the corona virus situation. I am sure this partnership will become a fruitful one and will unlock new doors for Prism as well.”
Detroit, MI, July 01, 2020: IBS Global Consulting, a global management consulting firm based in Detroit, is proud to announce that Tonya McNeal-Weary, Founder and Managing Director, has been appointed President, Northern USA – India Business Council of the Women’s Indian Chamber of Commerce and Industry (WICCI), the first independent National Business Chamber for women in India.
Supported by ALL Ladies League (ALL) and Women Economic Forum (WEF), the WICCI aims to bring about fundamental changes in governmental policies, laws and incentives with a key focus on encouraging and empowering women-owned businesses across all sectors to become more competitive in the business world.
Women face monumental challenges when it comes to accessing funding; confront glass ceilings in senior management roles and board positions; and struggle with excessive household and caregiving roles. WICCI and its Councils at National, Regional, State and City levels, as well as international, will suggest concrete steps and recommendations to relevant government authorities to help mitigate the many challenges women in business face, and uphold women’s interest in policy making at multiple levels to help women get better incentives, improved access to finance and other resources to empower businesswomen and entrepreneurs from all sectors.
“I am proud and deeply honored to accept the position as President, Northern USA – India Business Council of the WICCI and look forward to building a robust team of Council members to serve as the collective voices of millions of women, ensuring their economic participation and inclusive perspectives in all aspects of legislation and policy making,” said Tonya McNeal-Weary, Managing Director at IBS Global Consulting.
As a female business owner in a male-dominated industry, McNeal-Weary understands first-hand the unique challenges women face. In her newly appointed role with WICCI, McNeal-Weary will work with respective government bodies and institutions to advocate toward enabling policy changes, incentives and other structural changes that will support the development of women’s influence and impact in the economic mainstream. This will include organizing delegation visits to various public platforms and industry forums to promote trade, commerce and investment for women entrepreneurs.
Minneapolis, MN, July 01, 2020: Medicom Health is pleased to announce that Mercyhealth has chosen to deploy their Rx Savings Assistant® solution across the health system as part of the provider’s ongoing commitment to improving medication adherence and reducing patient readmissions.
Mercyhealth is a regional health system with seven hospitals and 85 primary and specialty care locations throughout 50 northern Illinois and southern Wisconsin communities. As an integrated health care provider, they provide exceptional, coordinated health care that spans four core service divisions: hospital-based services, clinic-based services, post-acute care and retail services, and a wholly owned insurance company.
Medicom Health’s new Rx Savings Assistant® software is a simple way for hospital systems to instantly increase prescription fills by making them more affordable for more patients. This technology supplements other patient assistance programs and leverages their electronic medical record (EMR) investment.
The solution is a plug-in module for EMRs like Epic and Cerner. The technology listens for new prescriptions and searches external databases for matching discount offers from various partners and adds those brand name and generic savings offers into the patient records automatically. The discounts are easily available on the printed After-Visit Summary (AVS) paperwork handed to each qualified patient at discharge. Because the system runs invisibly behind the scenes, it does not alter physician workflow or influence prescribing patterns. As soon as this solution is turned on, every qualified patient is eligible for effortless access to discounts for any prescription.
“Dramatically reducing the cost of medications for patients improves their adherence and ultimately their health,” says Will Sigsbee, CEO of Medicom Health. “We are able to make a meaningful impact for health systems because of the volume and quality of our discount offers, and reduced friction in delivering them.”
“We are always looking for ways to improve access to medications for our patients,” says Don Janczak, System Director of Pharmacy at Mercyhealth. “When patients have affordable medications, they are more likely to fill and follow them, which improves outcomes and reduces readmission rates. We are pleased to offer this service as another way to reduce our patients’ cost burden.”
Increased adherence results in many benefits to patients and providers, including better outcomes, patient satisfaction, pharmacy revenues, and more.
